Fluvastatin reduces the risk of fatal and serious nonfatal cardiac events by 22% in patients with average cholesterol levels after undergoing a first angioplasty, according to the Lescol Intervention Prevention Study.
Published in the Journal of the American Medical Association, the results support the early use of lipid-lowering therapy fluvastatin in these patients.
The four-year study followed 1677 patients recruited from 57 centres in 10 countries.
